Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 16, 2004. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2004.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 880,000 Ordinary shares of 25 pence each.
- Purchase Date: September 15, 2004.
- Price Per Share: 1,185.3365 pence.
- Treasury Holdings Post-Purchase: 44,173,000 shares.
- Shares in Issue (Excluding Treasury): 5,890,455,606 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company increased its treasury share holdings by 880,000 shares. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 880,000 share repurchase against the disclosed price of 1,185.3365 pence per share.
- Confirm the updated total share count (5,890,455,606 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2004, to understand the full scope of the share buyback authority granted.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial results.